Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Erectile Dysfunction - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H2 2016', provides an overview of the Erectile Dysfunction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Erectile Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Erectile Dysfunction - The report reviews pipeline therapeutics for Erectile Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Erectile Dysfunction therapeutics and enlists all their major and minor projects - The report assesses Erectile Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Erectile Dysfunction Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Erectile Dysfunction - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Erectile Dysfunction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Erectile Dysfunction Overview 10 Therapeutics Development 11 Pipeline Products for Erectile Dysfunction - Overview 11 Pipeline Products for Erectile Dysfunction - Comparative Analysis 12 Erectile Dysfunction - Therapeutics under Development by Companies 13 Erectile Dysfunction - Therapeutics under Investigation by Universities/Institutes 15 Erectile Dysfunction - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Erectile Dysfunction - Products under Development by Companies 20 Erectile Dysfunction - Products under Investigation by Universities/Institutes 22 Erectile Dysfunction - Companies Involved in Therapeutics Development 23 Apricus Biosciences, Inc. 23 Aytu BioScience, Inc. 24 Biopharm GmbH 25 Futura Medical Plc 26 Hanmi Pharmaceuticals, Co. Ltd. 27 Humanetics Corporation 28 IntelGenx Corp. 29 Ion Channel Innovations, LLC 30 Mezzion Pharma Co. Ltd. 31 Mitsubishi Tanabe Pharma Corporation 32 Monosol Rx, LLC 33 NAL Pharmaceuticals Ltd. 34 Palatin Technologies, Inc. 35 Pharmicell Co., Ltd. 36 Sihuan Pharmaceutical Holdings Group Ltd. 37 Suda Ltd 38 Yungjin Pharm. Co., Ltd. 39 Erectile Dysfunction - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Combination Products 41 Assessment by Target 42 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 (PDE-5 Inhibitor + tramadol hydrochloride) - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 alprostadil - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 AP-102 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 avanafil - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 BIO-300 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 BL-214 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Cellgram-ED - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 fadanafil - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 HCP-1302 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 HCP-1303 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 MED-2002 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 MED-2005 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 pVAX-hSlo - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 sildenafil citrate - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 sildenafil citrate - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 sildenafil citrate - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 Small Molecule to Inhibit PDE5 for Erectile Dysfunction - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 SUD-003 - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 T-6932 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 tadalafil - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 tadalafil - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 tadalafil - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 TF-0092 - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 TPN-729 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 TR-399 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 udenafil - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 VLFIA-330 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 YBH-1603 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 Erectile Dysfunction - Dormant Projects 93 Erectile Dysfunction - Discontinued Products 97 Erectile Dysfunction - Product Development Milestones 98 Featured News & Press Releases 98 Mar 28, 2016: MonoSol Rx Successfully Completes Pre-IND Meeting with the FDA for PharmFilm Tadalafil 98 Nov 25, 2015: iX Biopharma Announces Success Of Pilot Bioavailability Study For Pheonix 98 Jan 29, 2015: VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity 99 Nov 20, 2014: Auxilium Pharmaceuticals Presents STENDRA Data At SMSNA Scientific Meeting 99 Nov 03, 2014: Auxilium Pharmaceuticals To Present STENDRA Data At SMSNA Scientific Meeting 100 Sep 18, 2014: VIVUS and Auxilium Announce FDA Approval of STENDRA sNDA; STENDRA Now First and Only Oral Erectile Dysfunction Treatment Approved to Be Taken Approximately 15 Minutes Before Sexual Activity 100 Jul 09, 2014: New Grant Enables Humanetics to Evaluate Potential Treatment for Erectile Dysfunction in Prostate Cancer Patients 101 Apr 11, 2014: VIVUS To Present Clinical Data On Avanafil at European Association of Urology 102 Feb 24, 2014: IntelGenx Achieves Positive Bioequivalence Results for Erectile Dysfunction VersaFilm Tadalafil Product 102 Jan 21, 2014: VIVUS and Auxilium Announce FDA Acceptance of Supplemental Filing Seeking an Update of Prescribing Information for STENDRA (avanafil) 102 Aug 01, 2013: VIVUS Announces Commercial Supply Agreement With Sanofi to Produce Avanafil 103 Jun 26, 2013: Vivus Announces European Approval For Spedra For Treatment Of Erectile Dysfunction 103 Jun 19, 2013: Vivus Announces Positive Results From TA-501 Clinical Trial Of Stendra For Treatment Of Men With Erectile Dysfunction 105 Apr 25, 2013: Vivus Receives CHMP Positive Opinion For Spedra For Treatment Of Erectile Dysfunction In Adult Men 106 Jul 18, 2012: Zydus Urosciences Launches Udenafil For Treatment Of Erectile Dysfunction In India 106 Appendix 107 Methodology 107 Coverage 107 Secondary Research 107 Primary Research 107 Expert Panel Validation 107 Contact Us 107 Disclaimer 108
List of Tables
Number of Products under Development for Erectile Dysfunction, H2 2016 11 Number of Products under Development for Erectile Dysfunction - Comparative Analysis, H2 2016 12 Number of Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Comparative Analysis by Late Stage Development, H2 2016 16 Comparative Analysis by Clinical Stage Development, H2 2016 17 Comparative Analysis by Early Stage Development, H2 2016 18 Comparative Analysis by Unknown Stage Development, H2 2016 19 Products under Development by Companies, H2 2016 20 Products under Development by Companies, H2 2016 (Contd..1) 21 Products under Investigation by Universities/Institutes, H2 2016 22 Erectile Dysfunction - Pipeline by Apricus Biosciences, Inc., H2 2016 23 Erectile Dysfunction - Pipeline by Aytu BioScience, Inc., H2 2016 24 Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2016 25 Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2016 26 Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 27 Erectile Dysfunction - Pipeline by Humanetics Corporation, H2 2016 28 Erectile Dysfunction - Pipeline by IntelGenx Corp., H2 2016 29 Erectile Dysfunction - Pipeline by Ion Channel Innovations, LLC, H2 2016 30 Erectile Dysfunction - Pipeline by Mezzion Pharma Co. Ltd., H2 2016 31 Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 32 Erectile Dysfunction - Pipeline by Monosol Rx, LLC, H2 2016 33 Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd., H2 2016 34 Erectile Dysfunction - Pipeline by Palatin Technologies, Inc., H2 2016 35 Erectile Dysfunction - Pipeline by Pharmicell Co., Ltd., H2 2016 36 Erectile Dysfunction - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2016 37 Erectile Dysfunction - Pipeline by Suda Ltd, H2 2016 38 Erectile Dysfunction - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 39 Assessment by Monotherapy Products, H2 2016 40 Assessment by Combination Products, H2 2016 41 Number of Products by Stage and Target, H2 2016 43 Number of Products by Stage and Mechanism of Action, H2 2016 45 Number of Products by Stage and Route of Administration, H2 2016 47 Number of Products by Stage and Molecule Type, H2 2016 49 Erectile Dysfunction - Dormant Projects, H2 2016 93 Erectile Dysfunction - Dormant Projects (Contd..1), H2 2016 94 Erectile Dysfunction - Dormant Projects (Contd..2), H2 2016 95 Erectile Dysfunction - Dormant Projects (Contd..3), H2 2016 96 Erectile Dysfunction - Discontinued Products, H2 2016 97
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
